hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06362993, orgStudyIdInfo id: STUDY00021561, briefTitle: Breast Cancer Screening in Ghana, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-11, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Penn State University, class: OTHER, collaborators name: University of Ghana, descriptionModule briefSummary: This study is designed to test the feasibility of two intervention on promoting early screening for breast cancer in rural Ghana. In one intervention, screening for breast cancer, diabetes and hypertension will be offered together. In another intervention, a series of sessions with men will be conducted with a goal to change gender attitudes and increase support to women. The investigators' long-term goal is to test these interventions in a large-scale randomized controlled trial. The specific aims of this feasibility study are to: 1) refine the study materials, including the curriculum for the sessions with men, by consulting with an expert advisory committee and a local committee, and 2) determine the feasibility of the two interventions in four clinic zones in Yilo-Krobo district in eastern Ghana (1 clinic in control, 1 clinic in the first intervention, and 2 in the second intervention). This trial registration is for the second specific aim., conditionsModule conditions: Breast Cancer Female, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Bundling, interventions name: MEGH, outcomesModule primaryOutcomes measure: Clinical breast exam (CBE) utilization at the local clinic, eligibilityModule sex: FEMALE, minimumAge: 20 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06362980, orgStudyIdInfo id: BPI-1178-IIT01, briefTitle: A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations, acronym: EGFR, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-04-01, completionDateStruct date: 2026-04-01, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: National Cancer Center, China, class: OTHER, descriptionModule briefSummary: BPI-1178 is a novel, orally administered inhibitor of both cyclin-dependent kinase 4 (CDK4) and CDK6 kinase activity. This open-label investigator-initiated trial (IIT) phase I study was designed to evaluate the safety and efficacy of oral BPI-1178 in combination with osimertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) Mutations., conditionsModule conditions: NSCLC, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: BPI-1178, interventions name: Osimertinib, outcomesModule primaryOutcomes measure: Number of patients with dose-limiting toxicity (DLT), secondaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: Disease Control Rate (DCR), secondaryOutcomes measure: Duration of Response (DoR), secondaryOutcomes measure: Progression-Free Survival (PFS), secondaryOutcomes measure: Overall Survival (OS), secondaryOutcomes measure: Intracranial ORR (iORR), secondaryOutcomes measure: Intracranial DCR (iDCR), secondaryOutcomes measure: Intracranial DoR (iDoR), secondaryOutcomes measure: Intracranial Time to Progression (iTTP), secondaryOutcomes measure: Intracranial PFS (iPFS), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06362967, orgStudyIdInfo id: Anti-HLA antibody, briefTitle: The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-06-30, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Anhui Provincial Hospital, class: OTHER_GOV, descriptionModule briefSummary: Evaluation of the efficacy and safety of immunoadsorption or plasma exchange combined with rituximab and high-dose IVIG to reduce high titres of anti-HLA antibodies in patients prior to allogeneic haematopoietic stem cell transplantation, conditionsModule conditions: High Titers of Anti-HLA Antibody (MFI ≥5000), designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Immunoadsorption or plasma exchange combined with rituximab, high-dose IVIG, outcomesModule primaryOutcomes measure: Incidence of reduction of anti-HLA antibody MFI values to less than 5000 in subjects at the end of treatment, secondaryOutcomes measure: Incidence of primary graft failure, secondaryOutcomes measure: Incidence of TRM after allo-HSCT, secondaryOutcomes measure: Incidence of ineffective platelet transfusion after allo-HSCT, secondaryOutcomes measure: Cumulative incidence of neutrophil engraftment after allo-HSCT, secondaryOutcomes measure: Cumulative incidence of II-IV° acute GVHD, secondaryOutcomes measure: Cumulative incidence of relapse at 1 year post-transplant, secondaryOutcomes measure: Probability of overall survival post transplantation, secondaryOutcomes measure: Incidence of allergies and allergic reactions, secondaryOutcomes measure: Incidence of haemorrhagic events, secondaryOutcomes measure: Incidence of viral, bacterial and fungal infections, secondaryOutcomes measure: Incidence of hypocalcaemia, eligibilityModule sex: ALL, minimumAge: 14 Years, maximumAge: 60 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), city: Hefei, state: Anhui, zip: 230036, country: China, geoPoint lat: 31.86389, lon: 117.28083, hasResults: False
protocolSection identificationModule nctId: NCT06362941, orgStudyIdInfo id: NW-HGN-01, briefTitle: Evaluation of an Oral Hair Supplement to Improve Hair Strength and Support Growth in Women and Men, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-02-01, completionDateStruct date: 2025-03-30, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Nutraceutical Wellness Inc., class: INDUSTRY, descriptionModule briefSummary: A single-center, open-label, prospective study to demonstrate the efficacy of an oral supplement to improve the strength and support the growth of thinning hair in men and women with self-perceived hair thinning., conditionsModule conditions: Hair Thinning, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Single Group Assignment 6-month, single-center, prospective interventional study, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Nutrafol Women's Hair Growth Supplemnt, interventions name: Nutrafol Women's Balance Hair Growth Supplement, interventions name: Nutrafol Women's Vegan Hair Growth Supplement, interventions name: Nutrafol Women's Postpartum Hair Growth Supplement, interventions name: Nutrafol Men's Hair Growth Supplement, outcomesModule primaryOutcomes measure: Change in hair shaft diameter compared to baseline at Day 180., primaryOutcomes measure: Change in hair shaft diameter compared to baseline at Day 90., secondaryOutcomes measure: Change in broken hairs recovered from the hair pull test compared to baseline at Day 180, secondaryOutcomes measure: Change in broken hairs recovered from the hair pull test compared to baseline at Day 90, secondaryOutcomes measure: Change in hair breakage during the hair pull test compared to baseline at Day 180, secondaryOutcomes measure: Change in hair breakage during the hair pull test compared to baseline at Day 90, secondaryOutcomes measure: Change in the number of hairs recovered from the hair pull test compared to baseline at Day 180, secondaryOutcomes measure: Change in the number of hairs recovered from the hair pull test compared to baseline at Day 90, secondaryOutcomes measure: Subject Self-Perceived Improvement in Hair Quality at Day 180, secondaryOutcomes measure: Subject Self-Perceived Improvement in Hair Quality at Day 90, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Dermatology Consulting Services, city: High Point, state: North Carolina, zip: 27262, country: United States, contacts name: Zoe Draelos, role: CONTACT, phone: 336-841-2040, email: zdraelos@northstate.net, geoPoint lat: 35.95569, lon: -80.00532, hasResults: False
protocolSection identificationModule nctId: NCT06362928, orgStudyIdInfo id: CP-60005, briefTitle: Safety and Effectiveness of the Akura Thrombectomy System in the Treatment of Acute Pulmonary Embolism, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07, primaryCompletionDateStruct date: 2025-06, completionDateStruct date: 2025-08, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Akura Medical, class: INDUSTRY, descriptionModule briefSummary: This study is a prospective, single-arm, non-randomized, interventional, multicenter feasibility study to evaluate the safety and effectiveness of percutaneous mechanical thrombectomy using the Akura Thrombectomy System in subjects with acute pulmonary embolism (PE)., conditionsModule conditions: Pulmonary Embolism Acute, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: ATC System, outcomesModule primaryOutcomes measure: Effectiveness, primaryOutcomes measure: Safety: Composite of Major Adverse Device-Related Events, secondaryOutcomes measure: Safety: Composite of Major Adverse Events, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06362915, orgStudyIdInfo id: FMASUR66/2024, briefTitle: Analgesic Effect of Illiohypogastic & Ilioinguinal Nerve Block in TAVR - TF (Prospective Randomized Study), statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-02, primaryCompletionDateStruct date: 2024-07-15, completionDateStruct date: 2024-08-30, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Ain Shams University, class: OTHER, descriptionModule briefSummary: The purpose of the study is to compare the effect of illiohypogastric and ilioinguinal nerve block with the local infiltration with lidocaine in patients undergoing TAVI, conditionsModule conditions: Anesthesia, Local, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, maskingDescription: * Group (A): will receive blind local infiltration in femoral region on the operation side by an experienced anesthesiologist using 20 ml lidocaine 1% (9).* Group (B): will receive ultrasound-guided ilioinguinal/iliohypogastric nerve block using 20 ml Bupivicane 0.25% by an experienced anesthesiologist., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 52, type: ESTIMATED, armsInterventionsModule interventions name: Lidocaine, interventions name: Bupivacain, outcomesModule primaryOutcomes measure: Extra Demand of sedation, secondaryOutcomes measure: Patient and surgeon satisfaction, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: maha sadek El Derh, status: RECRUITING, city: Cairo, state: Heliopolis, zip: 11721, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, locations facility: Ain Shams University, status: RECRUITING, city: Cairo, country: Egypt, contacts name: maha S elDerh, Ass.prof, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06362902, orgStudyIdInfo id: NOSES-VIII B, briefTitle: Laparoscopic Right Hemicolectomy With Transrectal Specimen Extraction for Colon Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-09-01, completionDateStruct date: 2025-09-01, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: National Cancer Center, China, class: OTHER, descriptionModule briefSummary: The purpose of this study is to investigate the preliminary surgical outcomes of laparoscopic right hemicolectomy with transrectal specimen extraction. The hypothesis is that this type of natural orifice specimen extraction surgery (NOSES) could achieve good short-term and oncological outcomes for right colon cancer patients., conditionsModule conditions: Colon Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 37, type: ESTIMATED, armsInterventionsModule interventions name: Laparoscopic right hemicolectomy with transrectal specimen extraction, outcomesModule primaryOutcomes measure: The rate of postoperative complications, secondaryOutcomes measure: Operating time, secondaryOutcomes measure: Estimated blood loss, secondaryOutcomes measure: The time of first flatus, secondaryOutcomes measure: Postoperative hospitalization, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: National Cancer Center, status: RECRUITING, city: Beijing, state: Beijing, zip: 100000, country: China, contacts name: Haitao Zhou, M.D., role: CONTACT, phone: +8613381167333, email: zhouhaitao01745@163.com, contacts name: Yueyang Zhang, M.D., role: CONTACT, phone: +8613552910035, email: yyzhang0129@163.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06362889, orgStudyIdInfo id: HealMD-CBD-1, briefTitle: Evaluating Microneedling With CBD and Hempseed Oil for Acne Vulgaris Safety and Efficacy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2024-10, completionDateStruct date: 2024-11, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Rejuva Medical Aesthetics, class: OTHER, collaborators name: HealMD, LLC, descriptionModule briefSummary: This is a prospective, single center, open label study to assess the safety and effectiveness of microneedling with CBD and hempseed oil for the treatment of moderate to severe acne in adults 22-years of age or older.The objective of this exploratory study is to evaluate the safety and efficacy of HealMD's CBD with hempseed oil to reduce the appearance of moderate to severe facial acne., conditionsModule conditions: Acne Vulgaris (Disorder), designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Microneedling with CBD, outcomesModule primaryOutcomes measure: Primary efficacy endpoints, secondaryOutcomes measure: Secondary efficacy endpoints, eligibilityModule sex: ALL, minimumAge: 22 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Rejuva Medical Aesthetics, city: Los Angeles, state: California, zip: 90025, country: United States, contacts name: LaRyel A Waldon, B.S., role: CONTACT, phone: 424-644-2400, email: laryel@rejuvamedical.org, contacts name: Margaux Oldfield, role: CONTACT, phone: 4246442400, email: margaux@rejuvamedical.org, geoPoint lat: 34.05223, lon: -118.24368, hasResults: False
protocolSection identificationModule nctId: NCT06362876, orgStudyIdInfo id: BAlis, briefTitle: The Effect of Breastfeeding Counseling Based on Motivational Interviewing, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-09-15, primaryCompletionDateStruct date: 2024-08-15, completionDateStruct date: 2024-12-15, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Mersin University, class: OTHER, descriptionModule briefSummary: This research was planned to determine the effect of breastfeeding counseling based on motivational interviewing method and standard breastfeeding counseling on breastfeeding self-efficacy and breastfeeding results in women who had a cesarean section., conditionsModule conditions: Breastfeeding Counseling Based on Motivational Interviewing, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 74, type: ESTIMATED, armsInterventionsModule interventions name: Breastfeeding Counseling Based on Motivational Interviewing, interventions name: Standard Breastfeeding Consultancy, outcomesModule primaryOutcomes measure: Level of breastfeeding self-efficacy, primaryOutcomes measure: Level of breastfeeding self-efficacy, primaryOutcomes measure: Level of breastfeeding self-efficacy, primaryOutcomes measure: Level of breastfeeding self-efficacy, primaryOutcomes measure: Level of breastfeeding self-efficacy, primaryOutcomes measure: Breastfeeding Results Evaluation Form, primaryOutcomes measure: Breastfeeding Results Evaluation Form, primaryOutcomes measure: Breastfeeding Results Evaluation Form, primaryOutcomes measure: Breastfeeding Results Evaluation Form, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule locations facility: Mersin University, city: Mersin, zip: 33180, country: Turkey, geoPoint lat: 36.79526, lon: 34.61792, hasResults: False
protocolSection identificationModule nctId: NCT06362863, orgStudyIdInfo id: WDRY2024-K027, briefTitle: Evaluation of Enteral Nutrition Biscuits for Inducing Remission in Moderate-to-severe Crohn's Disease, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Ping An, class: OTHER, descriptionModule briefSummary: By conducting a randomized controlled study of the role of enteral nutrition biscuits in the induction of remission in moderate-to-severe Crohn's disease, we will evaluate to investigate the role of enteral nutrition biscuits in the induction and remission phases of moderate-to-severe Crohn's disease; to assess patient adherence to enteral nutrition biscuits and the timing of their application; to assess the role of enteral nutrition biscuits in biologically refractory patients; and to assess the role of enteral nutrition biscuits in the remission of perianal, small bowel, and colonic lesions., conditionsModule conditions: Crohn's Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This is a prospective randomized controlled study divided into intervention and control groups., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 52, type: ESTIMATED, armsInterventionsModule interventions name: enteral nutrition biscuits, outcomesModule primaryOutcomes measure: Crohn's disease activity index, CDAI, secondaryOutcomes measure: Induced remission success rate, secondaryOutcomes measure: Gastrointestinal Symptom Rating Scale (GSRS) score, secondaryOutcomes measure: Gastrointestinal symptom remission, secondaryOutcomes measure: Detection of antibody levels to the biologics used in sera from patients with secondary loss of response to the biologics, secondaryOutcomes measure: Incidence and severity of perianal lesions in both groups, secondaryOutcomes measure: Rate of endoscopic remission of small bowel and colon lesions in both groups, secondaryOutcomes measure: Changes in inflammatory biomarkers (C-reactive protein, fecal calreticulin) in both groups, secondaryOutcomes measure: Adverse events and serious adverse events, safety and tolerability, with treatment-related adverse events and number of occurrences as assessed by CTCAE v5.0, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False